Hayashi Reiko, Goto Yuya, Ikeda Ryuji, Yokoyama Kazunari K, Yoshida Kenichi
Laboratory of Molecular and Cellular Biology, Department of Life Sciences, School of Agriculture, Meiji University, 1-1-1 Higashimita, Kawasaki, Kanagawa 214-8571, Japan.
J Biol Chem. 2006 Nov 24;281(47):35633-48. doi: 10.1074/jbc.M603800200. Epub 2006 Sep 19.
The TRIP-Br1/p34(SEI-1) family proteins participate in cell cycle progression by coactivating E2F1- or p53-dependent transcriptional activation. Here, we report the identification of human CDCA4 (also know as SEI-3/Hepp) as a novel target gene of transcription factor E2F and as a repressor of E2F-dependent transcriptional activation. Analysis of CDCA4 promoter constructs showed that an E2F-responsive sequence in the vicinity of the transcription initiation site is necessary for the E2F1-4-induced activation of CDCA4 gene transcription. Chromatin immunoprecipitation analysis demonstrated that E2F1 and E2F4 bound to an E2F-responsive sequence of the human CDCA4 gene. Like TRIP-Br1/p34(SEI-1) and TRIP-Br2 (SEI-2), the transactivation domain of CDCA4 was mapped within C-terminal acidic region 175-241. The transactivation function of the CDCA4 protein was inhibited by E2F1-4 and DP2, but not by E2F5-8. Inhibition of CDCA4 transactivation activity by E2F1 partially interfered with retinoblastoma protein overexpression. Conversely, CDCA4 suppressed E2F1-3-induced reporter activity. CDCA4 (but not acidic region-deleted CDCA4) suppressed E2F1-regulated gene promoter activity. These findings suggest that the CDCA4 protein functions as a suppressor at the E2F-responsive promoter. Small interfering RNA-mediated knockdown of CDCA4 expression in cancer cells resulted in up-regulation of cell growth rates and DNA synthesis. The CDCA4 protein was detected in several human cells and was induced as cells entered the G1/S phase of the cell cycle. Taken together, our results suggest that CDCA4 participates in the regulation of cell proliferation, mainly through the E2F/retinoblastoma protein pathway.
TRIP-Br1/p34(SEI-1)家族蛋白通过共激活E2F1或p53依赖的转录激活参与细胞周期进程。在此,我们报告鉴定出人类CDCA4(也称为SEI-3/Hepp)是转录因子E2F的一个新靶基因,并且是E2F依赖的转录激活的一个抑制因子。对CDCA4启动子构建体的分析表明,转录起始位点附近的一个E2F反应序列对于E2F1-4诱导的CDCA4基因转录激活是必需的。染色质免疫沉淀分析证明E2F1和E2F4与人类CDCA4基因的一个E2F反应序列结合。与TRIP-Br1/p34(SEI-1)和TRIP-Br2 (SEI-2)一样,CDCA4的反式激活结构域定位于C末端酸性区域175-241内。CDCA4蛋白的反式激活功能被E2F1-4和DP2抑制,但不被E2F5-8抑制。E2F1对CDCA4反式激活活性的抑制部分干扰了视网膜母细胞瘤蛋白的过表达。相反,CDCA4抑制E2F1-3诱导的报告基因活性。CDCA4(而非缺失酸性区域的CDCA4)抑制E2F1调节的基因启动子活性。这些发现表明CDCA4蛋白在E2F反应性启动子处起抑制因子的作用。小干扰RNA介导的癌细胞中CDCA4表达的敲低导致细胞生长速率和DNA合成的上调。在几种人类细胞中检测到CDCA4蛋白,并且当细胞进入细胞周期的G1/S期时其被诱导。综上所述,我们的结果表明CDCA4主要通过E2F/视网膜母细胞瘤蛋白途径参与细胞增殖的调节。